DiaSorin gets FDA clearance for PCT assay
June 2018—DiaSorin received clearance from the FDA to market the Liaison Brahms PCT II Gen assay for the quantitative determination of procalcitonin.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Cascade Pathology Services joins Aurora Diagnostics
June 2018—Aurora Diagnostics announced that Cascade Pathology Services, a physician-owned multispecialty pathology practice providing surgical pathology services to hospitals and physician groups in the Portland area, has joined Aurora Diagnostics.
Beckman introduces Access Sensitive Estradiol
June 2018—Beckman Coulter Diagnostics launched its Access Sensitive Estradiol in the U.S. and in the majority of worldwide markets. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions.
SciGene FISH hybridizer
June 2018—SciGene introduced the CytoBrite Plus Slide Incubation System, a programmable FISH hybridizer with onboard temperature verification of each slide position, as required by CAP cytogenetics checklist item CYG.33950.
FDA-approved continuous glucose monitoring system
June 2018—Medtronic received FDA approval for its Guardian Connect continuous glucose monitoring system for people with diabetes ages 14 to 75 years.
BD launches ccfDNA blood collection tube in Europe
June 2018—Becton Dickinson announced the commercial availability of the CE-IVD-marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland.
IgG subclass antibodies
June 2018—Binding Site’s Immunologicals Group announced the availability of affinity-purified, unconjugated, anti-human antibodies to the IgG subclasses, including IgG1, IgG2, IgG3, and IgG4, for IVD research use in solid phase enzyme immunoassay based test methods, especially ELISAs, and other potential testing applications.
Genoptix completes Rosetta acquisition
June 2018—Rosetta Genomics’ stockholders have approved the acquisition of the company by Genoptix, which will immediately begin marketing, selling, and distributing Rosetta Genomics’ products.
POC immunoassay testing system
June 2018—Sekisui Diagnostics has partnered with Qualigen to distribute the FastPack IP System, Qualigen’s POC immunoassay testing system.
AdvantEdge acquires PMI, 5/18
May 2018—AdvantEdge Healthcare Solutions, a medical billing company, has acquired Professional Management, Inc., a Baltimore-based medical billing company that provides billing services to pathology, radiology, and emergency medicine physician groups.